nach oben

Drugs

Erschienen in:

01.08.2005 | Adis Drug Profile

Exenatide

verfasst von: Gillian M. Keating

Erschienen in: Drugs | Ausgabe 12/2005

Einloggen, um Zugang zu erhalten

Abstract

▴ Exenatide is an incretin mimetic. It improves glycaemic control via various glucoregulatory mechanisms, including glucose-dependent insulinotropism, suppression of inappropriately high glucagon levels, delayed gastric emptying and reduction of food intake.

▴ In three large, well designed, phase III trials in adults with type 2 diabetes mellitus and suboptimal glycaemic control despite treatment with metformin and/or a sulfonylurea, mean changes from baseline in glycosylated haemoglobin (HbA_1c) significantly favoured subcutaneous exenatide 5 or 10μg twice daily over placebo after 30 weeks’ treatment (primary endpoint).

▴ Relative to placebo, reductions from baseline in bodyweight were significantly greater with twice-daily exenatide 5 μg (in two studies) or 10μg (in all three studies).

▴ Post hoc completer analyses revealed that the beneficial effects of exenatide on HbA_1c and body-weight were maintained for up to 82 weeks.

▴ Adjunctive therapy with subcutaneous exenatide 10μg twice daily improved glycaemic control to a similar extent as insulin glargine in patients with type 2 diabetes suboptimally controlled with metformin plus a sulfonylurea in a large, well designed, 26-week, phase III trial.

▴ Subcutaneous exenatide was generally well tolerated in patients with type 2 diabetes. The incidence of hypoglycaemia in patients receiving exenatide plus metformin was similar to that seen in placebo plus metformin recipients; however, in patients receiving a sulfonylurea (with or without metformin), the incidence of hypoglycaemia was numerically higher with exenatide than with placebo.

The use of trade names is for product identification purposes only and does not imply endorsement.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352: 837–53CrossRef

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005 Jan; 28 Suppl. 1: S4–S36CrossRef

American College of Endrocrinology. American College of Endrocrinology consensus statement on guidelines for glycemic control. Endocr Pract 2002 Jan/Feb; 8 Suppl. 1: 5–11

Clemens A, Siegel E, Gallwitz B. Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids — update on the background of the current guidelines. Exp Clin Endocrinol Diabetes 2004 Oct; 112(9): 493–503PubMedCrossRef

Baron AD, Kim D, Weyer C. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metab Disord 2002; 2: 63–82CrossRef

UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995 Nov; 44: 1249–58CrossRef

Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77–88PubMedCrossRef

Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002 Mar; 87(3): 1282–90PubMedCrossRef

Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004 Sep; 53(9): 2397–403PubMedCrossRef

10.

Blase E, Taylor K, Gao H-Y, et al. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 2005 May; 45(5): 570–7PubMedCrossRef

11.

Edwards CMB, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001 Jul; 281 (1): E155-61

12.

Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003 Jul; 88(7): 3082–9PubMedCrossRef

13.

Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005 Jan 15; 62(2): 173–81PubMed

14.

Linnebjerg H, Kothare P, Skrivanek Z, et al. Exenatide: postprandial glucose pharmacodynamics at various dosing times relative to a meal in patients with type 2 diabetes [abstract no. 776]. Diabetologia 2004 Aug; 47 Suppl. 1: A280. Plus poster presented at the 40th Annual Meeting of the European Association for the Study of Diabetes; 2004 Sep 5–9; Munich

15.

Fehse F, Trautmann ME, Holst JJ, et al. Effects of exenatide on first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [abstract no. 772]. Diabetologia 2004 Aug; 47 Suppl. 1: A279

16.

Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003 Jun; 284(6): E1072–9PubMed

17.

Mari A, Halseth A, Nanayakkara N, et al. Mathematical modeling shows exenatide improved postprandial β-cell function in patients with type 2 diabetes treated with metformin or metformin and sulfonylurea [abstract no. 482-P]. Diabetes 2005; 54 Suppl. 1: A119. Plus poster presented at the 65th Annual Scientific Sessions of the American Diabetes Association; 2005 Jun 10–14; San Diego (CA)

18.

Hiles R, Carpenter T, Serota D, et al. Exenatide does not cause pancreatic islet cell proliferative lesions in rats and mice following 2-year exposure [abstract no. 1585-P]. Diabetes 2004 Jun; 53 Suppl. 2: A380

19.

Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob,db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999 May; 48: 1026–34PubMedCrossRef

20.

Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001 May; 50(5): 583–9PubMedCrossRef

21.

Joy SV, Rodgers PT, Scates AC. Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother 2005 Jan; 39(1): 110–8PubMed

22.

Amylin Pharmaceuticals, Inc. Byetta™ (exenatide injection): prescribing information [online]. Available from URL: http:// www.byetta.com [Accessed 2005 May 9]

23.

Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003 Aug; 26(8): 2370–7PubMedCrossRef

24.

Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005 Apr; 146(4): 2069–76PubMedCrossRef

25.

Soon D, Linnebjerg H, Chan C, et al. Effect of exenatide on digoxin pharmacokinetics [abstract no. PO-047]. Clin Exp Pharmacol Physiol 2004 Aug; 31 Suppl. 1: A65CrossRef

26.

Calara F, Taylor K, Han J, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005 Feb; 27(2): 210–5PubMedCrossRef

27.

Kothare P, Linnebjerg H, Atkins M, et al. Effect of exenatide on lisinopril pharmacodynamcis in patients treated for hypertension [abstract no. PI-24]. Clin Pharmacol Ther 2005 Feb; 77(2): P14CrossRef

28.

Linnebjerg H, Kothare P, Park S, et al. Exenatide pharmacokinetics in patients with mild to moderate renal dysfunction and end stage renal disease [abstract no. 469-P]. Diabetes 2005; 54 Suppl. 1: A116CrossRef

29.

Hiles RA, Bawdon RE, Petrella EM. Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4). Hum Exp Toxicol 2003 Dec; 22(12): 623–8PubMedCrossRef

30.

Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005 Jun; 7(3): 467–77PubMedCrossRef

31.

DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005 May; 28(5): 1092–100PubMedCrossRef

32.

Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 Nov; 27(11): 2628–35PubMedCrossRef

33.

Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 May; 28(5): 1083–91PubMedCrossRef

34.

Kim D, Trautmann ME, Herrmann K, et al. Exenatide reduzierte HbA_1c und gewicht über 82 wochen bei patienten mit typ-2 diabetes in kombination mit metformin [abstract no. V-20]. Diabetes Stoffwechsel 2005; 14 Suppl. 1: 10

35.

Kim D, Trautmann ME, Limmer J, et al. Exenatide reduzierte HbA_1c und gewicht über 82 wochen bei mit sulfonylharnstoff behandelten patienten mit typ-2 diabetes [abstract no. P-351]. Diabetes Stoffwechsel 2005; 14 Suppl. 1: 162

36.

Kim D, Trautmann ME, Schönamsgruber E, et al. Exenatide reduzierte HbA_1c und gewicht über 82 wochen bei mit metformin und sulfonylharnstoff behandelten patienten mit typ-2 diabetes [abstract no. P-349]. Diabetes Stoffwechsel 2005; 14 Suppl. 1: 161

37.

Kendall DM, Kim D, Poon T, et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 wk [abstract no. 16-OR]. Diabetes 2005; 54 Suppl. 1: A4–5

38.

Heine RJ, Van Gaal LF, Johns D, et al. Comparison of exenatide and insulin glargine in MET- and SU-treated patients with type 2 diabetes: exenatide achieved equivalent glycemic control, with weight reduction and less nocturnal hypoglycemia [abstract no. 9-OR]. Diabetes 2005; 54 Suppl. 1: A3. Plus oral presentation at the 65th Annual Scientific Sessions of the American Diabetes Association; 2005 Jun 10–14; San Diego (CA)

39.

Maggs D, Kim D, Holcombe J, et al. Exenatide-induced reductions in A1C and body weight in long-term trials are not explained by gastrointestinal side effects [abstract no. 485-P]. Diabetes 2005; 54 Suppl. 1: A120. Plus poster presented at the 65th Annual Scientific Sessions of the American Diabetes Association; 2005 Jun 10–14; San Diego (CA)

40.

Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004 Sep–Oct; 20(5): 411–7PubMedCrossRef

Titel: Exenatide
verfasst von: Gillian M. Keating
Publikationsdatum: 01.08.2005
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2005
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200565120-00008

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Exenatide

Abstract

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2005

A Comparative Review of the Options for Treatment of Erectile Dysfunction

Tipranavir: A Ritonavir-Boosted Protease Inhibitor

Exenatide

Rate versus Rhythm Control in Patients with Atrial Fibrillation

Tipranavir: A Ritonavir-Boosted Protease Inhibitor

Inhaled β2-Adrenoceptor Agonists